.png){kind=icon}
.png){kind=icon}
Return
Neoadjuvant and adjuvant therapy in uveal melanoma: toward systemic control of a systemic disease
.png){kind=icon}
OA
AI
D
C
D
I
P
S
S
H
D
DOI：10.1016/j.ctrv.2026.103181.png)
.png){kind=icon}
.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Uveal melanoma exhibits early dissemination with prolonged micrometastatic latency. • Minimal residual disease (MRD) persists as occult niches despite local control. • ctDNA enables dynamic risk-stratification and predicts survival. • Neoadjuvant darovasertib induces clinically meaningful tumor shrinkage. • Adjuvant tebentafusp is being evaluated for molecular residual disease in high-risk UM.
Keywords:
Uveal melanoma
minimal residual disease
micrometastases
neoadjuvant treatment
adjuvant treatment
liquid biopsy
circulating tumor DNA
AI Summary
Key information extracted from the uploaded paper, including a brief overview, abstract, background, key highlights, visual analysis, and future outlook.
Journal
IF:
10.5
Papers:
2.8K
Citations:
1.3W
Organization
Cited Papers